Cancer Genetics Plans $48.6M IPO | GenomeWeb

This article has been updated to correct information on the firm's tests.

NEW YORK (GenomeWeb News) – Cancer Genetics anticipates raising up to about $49 million in its initial public offering, the genomics-based test development company said in an amended Form S-1 filed last week with the US Securities and Exchange Commission.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.